The decisions of Ablexis’ partners to license the AlivaMab Mouse technology provide significant endorsements of the importance and value of the AlivaMab Mouse to their efforts in the discovery and development of human therapeutic antibodies. The licenses Ablexis provides are non-exclusive and the platform remains unencumbered, bringing zero target or field-of-use restrictions. The AlivaMab Mouse technology remains fully available for licensing to future partners.
Licensees of the AlivaMab
Ablexis has five launch customers, which were announced simultaneously as the Pharma Consortium. The consortium comprises five of the top 20 global pharmaceutical companies, including Pfizer, Inc. Ablexis continues expanding its ranks of announced licensees of the AlivaMab Mouse platform, demonstrating the ongoing broad availability and need for our technology by experienced antibody drug discovery and development organizations.